JAGSNPHARM · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 41/100 — Quality 54 · Valuation 25 · Momentum 37
| Share price | ₹223.02 |
| Market cap | ₹1,532 Cr |
| P/E ratio | 36.9 |
| P/B ratio | 5.9 |
| ROCE | 20.3% |
| Dividend yield | 1.08% |
| Book value | ₹39.40 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹287 Cr | ₹43 Cr | 16.9% |
| 2025 | ₹269 Cr | ₹55 Cr | 16.0% |
| 2024 | ₹209 Cr | ₹22 Cr | 10.4% |
| 2023 | ₹237 Cr | ₹27 Cr | 14.5% |
| 2022 | — | — | — |
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India.